Display options
Cite
Rubinstein MM, Goss C, Avecilla ST, et al. Management of thymoma-associated pure red cell aplasia: A novel use of blood substitute HBOC-201 in a Jehovah's Witness. Clin Case Rep. 2019;8(2):289-292doi: 10.1002/ccr3.2626.
Rubinstein, M. M., Goss, C., Avecilla, S. T., Dubé, G. P., Riely, G. J., & Mones, J. V. (2020). Management of thymoma-associated pure red cell aplasia: A novel use of blood substitute HBOC-201 in a Jehovah's Witness. Clinical case reports, 8(2), 289-292. https://doi.org/10.1002/ccr3.2626
Rubinstein, Maria M, et al. "Management of thymoma-associated pure red cell aplasia: A novel use of blood substitute HBOC-201 in a Jehovah's Witness." Clinical case reports vol. 8,2 (2020): 289-292. doi: https://doi.org/10.1002/ccr3.2626
Rubinstein MM, Goss C, Avecilla ST, Dubé GP, Riely GJ, Mones JV. Management of thymoma-associated pure red cell aplasia: A novel use of blood substitute HBOC-201 in a Jehovah's Witness. Clin Case Rep. 2019 Dec 26;8(2):289-292. doi: 10.1002/ccr3.2626. eCollection 2020 Feb. PMID: 32128175; PMCID: PMC7044386.
Copy Download .nbib Format: NLM
Share it on

Clin Case Rep. 2019 Dec 26;8(2):289-292. doi: 10.1002/ccr3.2626. eCollection 2020 Feb.

Management of thymoma-associated pure red cell aplasia: A novel use of blood substitute HBOC-201 in a Jehovah's Witness.

Clinical case reports

Maria M Rubinstein, Cheryl Goss, Scott T Avecilla, Gregory P Dubé, Gregory J Riely, Jodi V Mones

Affiliations

  1. Department of Medicine Memorial Sloan Kettering Cancer Center New York New York.
  2. Department of Laboratory Medicine Memorial Sloan Kettering Cancer Center New York New York.
  3. Hemoglobin Oxygen Therapeutics, LLC Waltham Massachusetts.

PMID: 32128175 PMCID: PMC7044386 DOI: 10.1002/ccr3.2626

Abstract

Pure red cell aplasia (PRCA) is a rare paraneoplastic syndrome occasionally associated with thymomas. Here, we report on the first ever use of a bovine hemoglobin-based oxygen carrier, HBOC-201 (HbO2 Therapeutics LLC; Hemopure

© 2019 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.

Keywords: hemoglobin‐based oxygen carrier; hemopure; pure red cell aplasia; red blood cell alternatives

Conflict of interest statement

JVM reports research funding from Janssen Pharmaceuticals. GJR reports grant and nonfinancial support from Novartis, Pfizer, Roche and Takeda. GPD is employed by Hemoglobin Oxygen Therapeutics, LLC. M

References

  1. Br J Haematol. 2006 Nov;135(3):405-7 - PubMed
  2. EuroIntervention. 2008 May;4(1):161-5 - PubMed
  3. Clin Chim Acta. 2018 Jul;482:33-39 - PubMed
  4. Shock. 2019 Oct;52(1S Suppl 1):92-99 - PubMed
  5. Haematologica. 2008 Jan;93(1):27-33 - PubMed
  6. Transfusion. 2014 Dec;54(12):3026-34 - PubMed

Publication Types

Grant support